Iranian Journal of Pathology

Association between FOXP3 Expression and Disease-Free Survival in Triple Negative Breast Cancer

Document Type : Original Research

Authors

Himawan Adhitama 1
Ery Kus Dwianingsih 1
Suwardjo Suwardjo 2
Teguh Aryandono 1

1 Department of Surgery, Surgical Oncology Division, Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University/Dr. Sardjito Hospital, Yogyakarta, Indonesia

2 Department of Anatomical Pathology, Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University/Dr. Sardjito Hospital, Yogyakarta, Indonesia

https://doi.org/10.30699/ijp.2025.2052684.3418
Abstract
Background & Objective: Triple-negative breast cancer (TNBC) is an aggressive subtype lacking estrogen, progesterone, and HER2 receptors, often leading to poor prognosis due to high recurrence and metastasis. FOXP3 expression, associated with suppressed anti-tumor immunity, is a potential prognostic marker in TNBC. However, the association between FOXP3 expression and disease-free survival (DFS) in TNBC remains controversial. This study aims to explore the relationship between FOXP3 expression and DFS in TNBC patients, contributing to the understanding of its prognostic significance.
Methods: This retrospective study included 47 TNBC patients. Immunohistochemistry examination assessed FOXP3 expression, which was then categorized into low and high expression based on an optimal cut-off point. Univariate and multivariate analyses were conducted using Cox regression test to determine association between variables and DFS. Survival analysis was assessed using the Kaplan-Meier method and the log-rank test.
Results: All patients were female mostly over 50 years old (66%). The majority had tumors >2 cm (87.2%) and LVI (66%). High-grade tumors (grade 3) were predominant (93.6%). Most patients showed moderate TIL levels (91.5%). No significant associations were found between FOXP3 expression and age (p=0.253), tumor size (p=0.308), lymph node status (p=0.466), tumor grade (p=0.476), LVI (p=0.422), patient's stage (p=0.644), and TILs (p=0.783). However, high FOXP3 expression was significantly associated with worse DFS (p=0.019). Additionally, a higher stage was associated with worse DFS (p=0.002).
Conclusion: High FOXP3 expression is associated with lower DFS in TNBC patients. FOXP3 expression was not associated with age, tumor size, lymph node status, tumor grade, LVI, TILs, or cancer stage.

Keywords

FOXP3 Protein
Disease-Free Survival
Triple Negative Breast Neoplasms

Subjects

  1. Sinaga ES, Ahmad RA, Shivalli S, Hutajulu SH. Age at diagnosis predicted survival outcome of female patients with breast cancer at a tertiary hospital in Yogyakarta, Indonesia. Pan African Medical Journal. 2018;31. [DOI:10.11604/pamj.2018.31.163.17284] [PMID] [PMCID]
  2. Anwar SL, Avanti WS, Nugroho AC, Choridah L, Dwianingsih EK, Harahap WA, et al. Risk factors of distant metastasis after surgery among different breast cancer subtypes: a hospital-based study in Indonesia. World J Surg Oncol. 2020 Dec 30;18(1):117. [DOI:10.1186/s12957-020-01893-w] [PMID] [PMCID]
  3. Hutajulu SH, Prabandari YS, Bintoro BS, Wiranata JA, Widiastuti M, Suryani ND, et al. Delays in the presentation and diagnosis of women with breast cancer in Yogyakarta, Indonesia: A retrospective observational study. PLoS One. 2022 Jan 13;17(1):e0262468. [DOI:10.1371/journal.pone.0262468] [PMID] [PMCID]
  4. Yin L, Duan JJ, Bian XW, Yu S cang. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Research. 2020 Dec 9;22(1):61. [DOI:10.1186/s13058-020-01296-5] [PMID] [PMCID]
  5. Zhang L, Wang XI, Ding J, Sun Q, Zhang S. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple-negative breast cancer. Ann Diagn Pathol. 2019 Jun;40:143-51. [DOI:10.1016/j.anndiagpath.2019.04.004] [PMID]
  6. Jamiyan T, Kuroda H, Yamaguchi R, Nakazato Y, Noda S, Onozaki M, et al. Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple-negative cancer of the breast. Breast Cancer. 2020 Sep 28;27(5):880-92. [DOI:10.1007/s12282-020-01084-1] [PMID] [PMCID]
  7. Jørgensen N, Hviid TVF, Nielsen LB, et al. Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer. Br J Cancer. 2021;125(10):1388-1398. [DOI:10.1038/s41416-021-01514-7] [PMID] [PMCID]
  8. Li J, Zhang X, Liu B, et al. The expression landscape of FOXP3 and its prognostic value in breast cancer. Ann Transl Med. 2022;10(14):801. [DOI:10.21037/atm-22-3080] [PMID] [PMCID]
  9. Semiglazov V, Tseluiko A, Kudaybergenova A, Artemyeva A, Krivorotko P, Donskih R. Immunology and immunotherapy in breast cancer. Cancer Biol Med. 2022 Jun 9;19(5):609-18. [DOI:10.20892/j.issn.2095-3941.2021.0597] [PMID] [PMCID]
  10. Dąbrowska A, Grubba M, Balihodzic A, Szot O, Sobocki BK, Perdyan A. The Role of Regulatory T Cells in Cancer Treatment Resistance. International Journal of Molecular Sciences. 2023; 24(18):14114. [DOI:10.3390/ijms241814114] [PMID] [PMCID]
  11. Li, Y., Zhang, C., Jiang, A. et al. Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review. J Transl Med 22, 293. 2024. [DOI:10.1186/s12967-024-05104-y] [PMID] [PMCID]
  12. Kim S, Lee A, Lim W, Park S, Cho MS, Koo H, et al. Zonal Difference and Prognostic Significance of Foxp3 Regulatory T Cell Infiltration in Breast Cancer. J Breast Cancer. 2014;17(1):8. [DOI:10.4048/jbc.2014.17.1.8] [PMID] [PMCID]
  13. Deng L, Li L, Qiu Y, Cao Y, Lian S, Si Y. Preoperative Platelet-Lymphocyte Ratio (PLR) as a prognostic inflammation biomarker in Asian HIV-infected patients with gastric cancer: a single-center study. BMC Gastroenterol. 2023;23(1):187. 2023 May 26. [DOI:10.1186/s12876-023-02828-x] [PMID] [PMCID]
  14. Hothorn, T, Lausen, T. On the exact distribution of maximally selected rank statistics, Computational Statistics & Data Analysis, Volume 43, Issue 2, 2003, Pages 121-137, ISSN 0167-9473, [DOI:10.1016/S0167-9473(02)00225-6.]
  15. Ogłuszka M, Orzechowska M, Jędroszka D, Witas P, Bednarek AK. Evaluate Cutpoints: Adaptable continuous data distribution system for determining survival in Kaplan-Meier estimator. Comput Methods Programs Biomed. 2019;177:133-139. [DOI:10.1016/j.cmpb.2019.05.023] [PMID]
  16. Berben L, Floris G, Kenis C, Dalmasso B, Smeets A, Vos H, et al. Age‐related remodelling of the blood immunological portrait and the local tumor immune response in patients with luminal breast cancer. Clin Transl Immunology. 2020 3;9(10). [DOI:10.1002/cti2.1184] [PMID] [PMCID]
  17. Takenaka M, Seki N, Toh U, Hattori S, Kawahara A, Yamaguchi T, et al. FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. Mol Clin Oncol. 2013; 1(4):625-32. [DOI:10.3892/mco.2013.107] [PMID] [PMCID]
  18. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, et al. Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse. J Clin Oncol. 2006 Dec 1;24(34):5373-80. [DOI:10.1200/JCO.2006.05.9584] [PMID]
  19. Glajcar A, Łazarczyk A, Tyrak KE, Hodorowicz-Zaniewska D, Streb J, Okoń K, et al. Nodal status in luminal A invasive breast cancer: relationships with cytotoxic CD8 + and regulatory FOXP3 + cells tumor-associated infiltrate and other prognostic factors. Virchows Archiv. 2021 Nov 12;479(5):871-82. [DOI:10.1007/s00428-021-03126-1] [PMID] [PMCID]
  20. Indiralia A, Rahniayu A, Mustokoweni S. Perbedaan Ekspresi Foxp3+ dan Cd8+ Tumor Infiltrating Lymphocytes Karsinoma Payudara pada Berbagai Stadium T. Indonesian J Cancer. 2018;12(1):7. [DOI:10.33371/ijoc.v12i1.549]
  21. Sudarsa IW, Subawa DG, Adiputra PAT, Manuaba IBTW. Correlation of CD8+ Expression, Foxp3+ Expression, and CD8+/Foxp3+ Ratio with Triple Negative Breast Cancer Stage in Sanglah General Hospital. Open Access Maced J Med Sci. 2019 ;7(10):1593-6. [DOI:10.3889/oamjms.2019.453] [PMID] [PMCID]
  22. deLeeuw RJ, Kroeger DR, Kost SE, Chang PP, Webb JR, Nelson BH. CD25 Identifies a Subset of CD4+FoxP3− TIL That Are Exhausted Yet Prognostically Favorable in Human Ovarian Cancer. Cancer Immunol Res. 2015;3(3):245-53. [DOI:10.1158/2326-6066.CIR-14-0146] [PMID]
  23. Shang B, Liu Y, Jiang S Juan, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015 ;5(1):15179. [DOI:10.1038/srep15179] [PMID] [PMCID]
  24. Jiang D, Gao Z, Cai Z, Wang M, He J. Clinicopathological and prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in patients with breast cancer: a meta-analysis. BMC Cancer. 2015;15(1):727. [DOI:10.1186/s12885-015-1742-7] [PMID] [PMCID]
  25. Yeong J, Thike AA, Lim JCT, Lee B, Li H, Wong SC, et al. Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer. Breast Cancer Res Treat. 2017;163(1):21-35. [DOI:10.1007/s10549-017-4161-4] [PMID]
  26. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Mènard S, et al. FOXP3 Expression and Overall Survival in Breast Cancer. J Clin Oncol. 2009;27(11):1746-52. [DOI:10.1200/JCO.2008.17.9036] [PMID]
  27. Aryandono T, Harijadi, Soeripto. Survival from operable breast cancer: prognostic factors in Yogyakarta, Indonesia. Asian Pac J Cancer Prev. 2006 Jul-Sep;7(3):455-9. [PMID]
  28. Mahmoud SMA, Paish EC, Powe DG, Macmillan RD, Lee AHS, Ellis IO, et al. An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat. 2011;127(1):99-108. [DOI:10.1007/s10549-010-0987-8] [PMID]
Iranian Journal of Pathology
Volume 20, Issue 4
Summer 2025
Pages 386-393

  • Receive Date 19 February 2025
  • Revise Date 26 March 2025
  • Accept Date 02 June 2025

Home

Guide for Authors

Submit Manuscript

Contact Us